|Bid||3.5000 x 1200|
|Ask||3.7900 x 900|
|Day's Range||3.5400 - 3.6500|
|52 Week Range||1.7000 - 3.8600|
|Beta (5Y Monthly)||1.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 08, 2023 - Aug 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.30|
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Shares of Accuray (NASDAQ: ARAY) were up by more than 15% early Thursday afternoon after the healthcare company released its fiscal 2023 third-quarter earnings Wednesday afternoon. The radiation oncology device specialist makes the CyberKnife and Tomo Therapy systems, which deliver radiosurgery, stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The fiscal quarter, which ended March 31, was the company's first in the black since its fiscal 2022 second quarter (i.e., calendar Q4 2021).
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Accuray Incorporated ( NASDAQ:ARAY ) is definitely a...
Key Insights Given the large stake in the stock by institutions, Accuray's stock price might be vulnerable to their...
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Shares of Accuray (NASDAQ: ARAY) were up as much as 17.6% on Thursday. The medical instruments maker, which specializes in radiation oncology machines, released its fiscal 2023 second-quarter earnings report late Wednesday. In the second-quarter report, CEO Suzanne Winter said the company set a record with 29 new systems delivered.
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The nature of investing is that you win some, and you lose some. Anyone who held Accuray Incorporated ( NASDAQ:ARAY...
Accuray ( NASDAQ:ARAY ) First Quarter 2023 Results Key Financial Results Revenue: US$96.5m (down 10% from 1Q 2022). Net...
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.
Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.
DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).